Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: Explore the inspiring stories of the Fierce 50
Alnylam Pharmaceuticals
Biotech
Roche's bet pays off as Alnylam hypertension med hits in phase 2
Roche’s splash into the metabolic pool appears to be paying off, with its Alnylam-partnered hypertension med reducing blood pressure in phase 2.
James Waldron
Sep 7, 2023 8:55am
BridgeBio lifts the hood on phase 3 acoramidis data
Aug 28, 2023 11:21am
Agios pays $17.5M for Alnylam's siRNA blood disease program
Aug 3, 2023 8:40am
Alnylam's RNAi approach to Alzheimer's reaches biomarker target
Jul 17, 2023 2:21am
Orbital raises $270M for next-gen RNA meds, loops in 2 new execs
Apr 26, 2023 6:00am
Alnylam culls 3 programs, including once-touted nephropathy med
Dec 16, 2022 1:52pm
